Results 1 to 10 of about 3,332 (166)

Zanubrutinib for the treatment of patients with del(17p) and/or TP53 CLL/SLL: analysis across clinical studies. [PDF]

Blood Adv
: Patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who harbor del(17p) and/or tumor protein p53 (TP53) mutations represent a high-risk population with a historically poor prognosis.
Tam CS, Anderson MA, Šimkovič M, Ghia P, Flinn IW, Laribi K, Opat S, Cull G, Munir T, Österborg A, Tedeschi A, Wang M, Szeto A, Allewelt H, Salmi T, Li J, Xu L, Wu K, Vezan R, Shadman M, Brown JR.   +20 more
europepmc   +2 more sources

Zanubrutinib as a salvage therapy for ibrutinib-resistant chronic lymphocytic leukemia: a case report. [PDF]

Front Oncol
ObjectivesThis case report aims to evaluate the efficacy of zanubrutinib, a next-generation Bruton tyrosine kinase inhibitor (BTKi), in achieving durable disease control for patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL ...
Lv Z, Lu P, Jing C, Yi X, Wu X.
europepmc   +2 more sources

Real-World Treatment Patterns and Outcomes of Zanubrutinib in Chronic Lymphocytic Leukemia and Small Lymphocytic Leukemia (CLL/SLL). [PDF]

Cancer Med
Zanubrutinib is a next‐generation selective Bruton's tyrosine kinase inhibitor (BTKi) with superior efficacy and lower cardiotoxicity rates seen in clinical trials over first‐generation ibrutinib in CLL/SLL patients.
Krackeler ML, Chee BH, Orchanian AK, Liu R, Law L, Zhu S, Zhu Z, Sakoda LC, Buchanan S, Massoudi M, Lopez A, Tavakoli J.   +11 more
europepmc   +2 more sources

Hypertension in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma in ALPINE: a secondary analysis. [PDF]

Blood Neoplasia
: Hypertension is a common side effect of Bruton tyrosine kinase inhibitors (BTKis). The second-generation BTKi zanubrutinib has high BTK selectivity, which may minimize off-target effects.
Rhee JW, Lamanna N, Aldairy W, Chen L, Zhang J, Ramirez D, White WB.   +6 more
europepmc   +2 more sources

Indirect Comparisons of the Efficacy and Safety of Zanubrutinib versus Venetoclax plus Obinutuzumab in Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. [PDF]

Oncol Ther
Introduction Compared with chemoimmunotherapy, both zanubrutinib monotherapy and venetoclax plus obinutuzumab prolong progression-free survival (PFS) in patients with chronic lymphocytic leukemia (CLL). Matching-adjusted indirect comparison (MAIC) can be
Munir T, Martinez-Calle N, Xu S, Yang K, Ge X, Ali AK, Mohseninejad L, Dobi B, Rakonczai P, Ma H, Williams R, Aldairy W, Lamanna N.   +12 more
europepmc   +2 more sources

Zanubrutinib is well tolerated and effective in patients with CLL/SLL intolerant of ibrutinib/acalabrutinib: updated results. [PDF]

Blood Adv
: Bruton tyrosine kinase (BTK) inhibitors such as ibrutinib (ibr) revolutionized chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) treatment, although treatment-related toxicities limit the use of some BTK inhibitors.
Shadman M, Burke JM, Cultrera J, Yimer HA, Zafar SF, Misleh J, Rao SS, Farber CM, Cohen A, Yao H, Idoine A, An Q, Flinn IW, Sharman JP.   +13 more
europepmc   +2 more sources

Therapeutic Impact of Zanubrutinib in Chronic Lymphocytic Leukemia: Evidence from a Systematic Review and Single-Arm Meta-Analysis. [PDF]

Pharmaceuticals (Basel)
Background and Objective: Zanubrutinib, a next-generation Bruton’s tyrosine kinase inhibitor (BTKi), has demonstrated promising efficacy in chronic lymphocytic leukemia (CLL), including treatment-naïve (TN) and relapsed/refractory (R/R) patients. However,
Alatawi Y, Alanazi FE, Alattar A, Alshaman R, Ramadan YN, Sayad R, Hetta HF.   +6 more
europepmc   +2 more sources

Zanubrutinib: past, present, and future

Blood Cancer Journal, 2023
In recent years, Bruton tyrosine kinase (BTK) inhibitors have provided significant advances in the treatment of patients with B-cell malignancies. Ibrutinib was the first BTK inhibitor to be approved, and it changed the standard-of-care treatment for ...
Constantine S. Tam, Javier L. Muñoz, John F. Seymour, Stephen Opat   +3 more
doaj   +3 more sources

Efficacy of zanubrutinib versus acalabrutinib for relapsed or refractory chronic lymphocytic leukemia (R/R CLL): a matching-adjusted indirect comparison (MAIC). [PDF]

Ther Adv Med Oncol
Background: There are no head-to-head studies comparing the efficacy of the Bruton tyrosine kinase inhibitors, zanubrutinib and acalabrutinib, in relapsed or refractory chronic lymphocytic leukemia (R/R CLL).
Shadman M, Brown JR, Williams R, Mohseninejad L, Yang K, Rakonczai P, Lamanna N, Xu S, Cleary Cohen A, O'Brien SM, Tedeschi A, Tam CS.   +11 more
europepmc   +2 more sources

Cost impact of Bruton's tyrosine kinase inhibitor selection in Medicare patients with chronic lymphocytic leukemia. [PDF]

J Comp Eff Res
Aim: To estimate cost savings associated with covalent Bruton’s tyrosine kinase inhibitor (cBTKi) choice in patients with treatment-naive (TN) and relapsed/refractory (RR) chronic lymphocytic leukemia (CLL) from a Medicare perspective.
Kittai AS, Patel DA, Shafrin J, Zawadzki N, Shetty VS, Barqawi YK, Rhodes JM.   +6 more
europepmc   +2 more sources